IBDEI0LB ; ; 04-FEB-2020
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 04, 2020
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,999) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,9449,1,4,0)
 ;;=4^S02.609A
 ;;^UTILITY(U,$J,358.3,9449,2)
 ;;=^5020372
 ;;^UTILITY(U,$J,358.3,9450,0)
 ;;=S02.2XXA^^72^643^26
 ;;^UTILITY(U,$J,358.3,9450,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,9450,1,3,0)
 ;;=3^Closed Fx,Nasal Bones
 ;;^UTILITY(U,$J,358.3,9450,1,4,0)
 ;;=4^S02.2XXA
 ;;^UTILITY(U,$J,358.3,9450,2)
 ;;=^5020306
 ;;^UTILITY(U,$J,358.3,9451,0)
 ;;=R22.1^^72^643^4
 ;;^UTILITY(U,$J,358.3,9451,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,9451,1,3,0)
 ;;=3^Localized Swelling,Mass and Lump,Neck
 ;;^UTILITY(U,$J,358.3,9451,1,4,0)
 ;;=4^R22.1
 ;;^UTILITY(U,$J,358.3,9451,2)
 ;;=^5019285
 ;;^UTILITY(U,$J,358.3,9452,0)
 ;;=E03.9^^72^644^35
 ;;^UTILITY(U,$J,358.3,9452,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,9452,1,3,0)
 ;;=3^Hypothyroidism
 ;;^UTILITY(U,$J,358.3,9452,1,4,0)
 ;;=4^E03.9
 ;;^UTILITY(U,$J,358.3,9452,2)
 ;;=^5002476
 ;;^UTILITY(U,$J,358.3,9453,0)
 ;;=E11.65^^72^644^3
 ;;^UTILITY(U,$J,358.3,9453,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,9453,1,3,0)
 ;;=3^Type 2 DM w/ Hyperglycemia
 ;;^UTILITY(U,$J,358.3,9453,1,4,0)
 ;;=4^E11.65
 ;;^UTILITY(U,$J,358.3,9453,2)
 ;;=^5002663
 ;;^UTILITY(U,$J,358.3,9454,0)
 ;;=E83.51^^72^644^26
 ;;^UTILITY(U,$J,358.3,9454,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,9454,1,3,0)
 ;;=3^Hypocalcemia
 ;;^UTILITY(U,$J,358.3,9454,1,4,0)
 ;;=4^E83.51
 ;;^UTILITY(U,$J,358.3,9454,2)
 ;;=^60542
 ;;^UTILITY(U,$J,358.3,9455,0)
 ;;=E83.52^^72^644^39
 ;;^UTILITY(U,$J,358.3,9455,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,9455,1,3,0)
 ;;=3^Hypercalcemia
 ;;^UTILITY(U,$J,358.3,9455,1,4,0)
 ;;=4^E83.52
 ;;^UTILITY(U,$J,358.3,9455,2)
 ;;=^59932
 ;;^UTILITY(U,$J,358.3,9456,0)
 ;;=E87.5^^72^644^23
 ;;^UTILITY(U,$J,358.3,9456,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,9456,1,3,0)
 ;;=3^Hyperkalemia
 ;;^UTILITY(U,$J,358.3,9456,1,4,0)
 ;;=4^E87.5
 ;;^UTILITY(U,$J,358.3,9456,2)
 ;;=^60041
 ;;^UTILITY(U,$J,358.3,9457,0)
 ;;=C64.9^^72^644^33
 ;;^UTILITY(U,$J,358.3,9457,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,9457,1,3,0)
 ;;=3^Malig Neopl of Kidney
 ;;^UTILITY(U,$J,358.3,9457,1,4,0)
 ;;=4^C64.9
 ;;^UTILITY(U,$J,358.3,9457,2)
 ;;=^5001250
 ;;^UTILITY(U,$J,358.3,9458,0)
 ;;=E03.5^^72^644^36
 ;;^UTILITY(U,$J,358.3,9458,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,9458,1,3,0)
 ;;=3^Myxedema Coma
 ;;^UTILITY(U,$J,358.3,9458,1,4,0)
 ;;=4^E03.5
 ;;^UTILITY(U,$J,358.3,9458,2)
 ;;=^5002474
 ;;^UTILITY(U,$J,358.3,9459,0)
 ;;=E05.91^^72^644^38
 ;;^UTILITY(U,$J,358.3,9459,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,9459,1,3,0)
 ;;=3^Thyroid Storm
 ;;^UTILITY(U,$J,358.3,9459,1,4,0)
 ;;=4^E05.91
 ;;^UTILITY(U,$J,358.3,9459,2)
 ;;=^5002493
 ;;^UTILITY(U,$J,358.3,9460,0)
 ;;=E05.80^^72^644^37
 ;;^UTILITY(U,$J,358.3,9460,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,9460,1,3,0)
 ;;=3^Hyperthyroidism
 ;;^UTILITY(U,$J,358.3,9460,1,4,0)
 ;;=4^E05.80
 ;;^UTILITY(U,$J,358.3,9460,2)
 ;;=^5002491
 ;;^UTILITY(U,$J,358.3,9461,0)
 ;;=E10.65^^72^644^4
 ;;^UTILITY(U,$J,358.3,9461,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,9461,1,3,0)
 ;;=3^Type 1 DM w/ Hyperglycemia
 ;;^UTILITY(U,$J,358.3,9461,1,4,0)
 ;;=4^E10.65
 ;;^UTILITY(U,$J,358.3,9461,2)
 ;;=^5002623
 ;;^UTILITY(U,$J,358.3,9462,0)
 ;;=E13.11^^72^644^8
 ;;^UTILITY(U,$J,358.3,9462,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,9462,1,3,0)
 ;;=3^Diabetic Ketoacidosis w/ Coma
 ;;^UTILITY(U,$J,358.3,9462,1,4,0)
 ;;=4^E13.11
